Fraile M, Castell J, Buxeda M, Cuartero A, Cantarell C, Domenech-Torné F M
Nuclear Medicine Service, Hospital General Vall d'Hebron. Barcelona, Spain.
Eur J Nucl Med. 1989;15(12):776-9. doi: 10.1007/BF00255496.
99mTc-MAG3 has been proposed as a replacement for both 131I-hippuran and 99mTc-DTPA on clinical grounds. We undertook a prospective preliminary study to ascertain whether 99mTc-MAG3 works better than 99mTc-DTPA in the follow up of renal transplant recipients. Seventeen patients (21 renograms each MAG3 and DTPA) were studied, together, with a reference group of 10 patients in whom MAG3 and Hippuran clearance rates were determined simultaneously. As expected, 99mTc-MAG3 analog images were excellent and 99mTcMAG3 clearance correlated very well with 131I-hippuran clearance (r = 0.978). MAG3 values were 60% of hippuran values. However, when the corresponding renographic and perfusion findings were faced with different diagnostic challenges, such as post transplant renal failure and rejection, 99mTc MAG3 did not differ from 99mTc-DTPA in a significant way. 99mTc-DTPA was superior to 99mtc-MAG3 in one case of rejection.
基于临床理由,99mTc-MAG3已被提议作为131I-马尿酸和99mTc-DTPA的替代物。我们进行了一项前瞻性初步研究,以确定在肾移植受者的随访中,99mTc-MAG3是否比99mTc-DTPA效果更好。研究了17例患者(每种药物各有21次肾图检查),同时设立了一个由10例患者组成的参照组,在该组中同时测定了MAG3和马尿酸的清除率。正如预期的那样,99mTc-MAG3的模拟图像极佳,99mTc-MAG3的清除率与131I-马尿酸的清除率相关性非常好(r = 0.978)。MAG3的值为马尿酸值的60%。然而,当相应的肾图和灌注结果面临不同的诊断挑战,如移植后肾衰竭和排斥反应时,99mTc-MAG3与99mTc-DTPA并无显著差异。在1例排斥反应中,99mTc-DTPA优于99mTc-MAG3。